N-acetylglucosamine for Crohn's disease
Part of Digestive system clinical trials.
This trial tests if a supplement called N-acetylglucosamine (GlcNAc) can help manage Crohn's disease symptoms. It may reduce inflammation in the gut if you have mild to moderate disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 80 years old
- Crohn's disease affecting the last part of the small intestine or both small and large intestine
- On stable medication for Crohn's for at least 8 weeks (including biologics and other treatments)
- Symptoms are not severe (a specific score less than 450)
- Willing to have genetic testing for ZIP8 gene
- No steroid use in the past 4 weeks
- No antibiotic use in the past 2 weeks
- Willing to provide recent endoscopy and imaging results
- Use effective birth control during study and for 30 days after (if you could become pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This trial tests a new, gentler way to diagnose Crohn's disease. If you have symptoms like long-lasting diarrhea or belly pain, this study may help find out if you have Crohn's without invasive procedures.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This trial tests whether adding a special liquid diet (partial enteral nutrition) to a new advanced Crohn's medication can help control disease better than the medication alone.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.